Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer

Jason S. Krumholtz, Jeff M. Michalski, Chandru P. Sundaram

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Health-related quality of life must be a factor when treatment options are discussed with a patient. Quality of life is measured by validated questionnaires that include generic and disease-targeted measures. Urinary and rectal symptoms and sexual function are evaluated after treatment for prostate cancer. Quality of life is adversely affected in the early post- brachytherapy period primarily by the urinary morbidity. Urinary symptoms peak 2 months after treatment and decline thereafter, although severe long- term urinary toxicity occurs in 3% to 12% of patients. Urinary symptoms are generally treated with alpha-blocker and anticholinergic drugs, but 2% to 5% of patients require transurethral resection of the prostate to relieve persistent obstruction. However, 6 months after treatment, overall satisfaction is excellent, and the majority of patients would recommend the procedure to a friend.

Original languageEnglish (US)
Pages (from-to)371-374
Number of pages4
JournalJournal of Endourology
Volume14
Issue number4
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer'. Together they form a unique fingerprint.

  • Cite this